← Leaderboards
Stuart L Goldstein
Cincinnati Childrens Hosp Med Ctr
$3,454,936
Attributed
$5,837,366
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2012–19$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,366,425 · 2
AHRQ$1,494,548 · 1
FDA$976,393 · 1
By mechanism
R01$3,817,744 · 2
R18$1,494,548 · 1
P50$525,074 · 1
Top collaborators
- David Joseph Askenazi5 shared
- Sangeeta Hingorani5 shared
- H. David Humes3 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- James Cnota$9,943,565
- Michael R. Bennett$733,013
- Ronald Mark Payne$3,741,089
- Catherine Dent Krawczeski$697,000
Others in their field
Top investigators on “Urine”
- Mine Cicek · Mayo Clinic Rochester$86,568,868
- Leonardo Trasande · New York University School Of Medicine$84,682,159
- Stephen Norman Thibodeau · Mayo Clinic Rochester$70,215,522
- Elaine D. Eaker · Eaker Epidemiology Enterprises, Llc$63,680,802
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,278,895
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$59,018,877
Research focus
UrineAcute Renal Failure With Renal Papillary NecrosisDiagnosisCreatinineKidneyPreventInjuryKidney DiseasesOperative Surgical ProceduresAnimalsChildhoodSerumAcuteBiological MarkersUnited States National Institutes Of HealthRandomizedAreaAdultCohortChronicGelatinase ABiological FactorsBiologicalAlbuminuria
Grant awards (16)
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)$628,742
R01 · FY2019 · DK
Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury$177,778
R01 · FY2018 · FD
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)$642,488
R01 · FY2017 · DK
Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in Children$497,585
R18 · FY2017 · HS · contact PI
Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury$399,483
R01 · FY2017 · FD
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)$640,887
R01 · FY2016 · DK
Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in Children$498,321
R18 · FY2016 · HS · contact PI
AKI: Biomarker Guided Therapies$98,691
P50 · FY2016 · DK · contact PI
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)$600,408
R01 · FY2015 · DK
Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in Children$498,642
R18 · FY2015 · HS · contact PI
Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury$399,132
R01 · FY2015 · FD
AKI: Biomarker Guided Therapies$101,025
P50 · FY2015 · DK · contact PI
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)$328,826
R01 · FY2014 · DK
AKI: Biomarker Guided Therapies$103,311
P50 · FY2014 · DK · contact PI
AKI: Biomarker Guided Therapies$101,073
P50 · FY2013 · DK · contact PI
AKI: Biomarker Guided Therapies$120,974
P50 · FY2012 · DK · contact PI